Compare BioNTech SE - ADR (BNTX) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Plby Group Inc — how do they compare? BioNTech SE - ADR trades at $90.28 (market cap $22.86B), while Plby Group Inc trades at $1.18 (market cap $136.40M). The key difference: BioNTech SE - ADR is far larger — about 167.6× Plby Group Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| BNTX | PLBY | |
|---|---|---|
Market Cap | $22.86B | $136.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $2.71 |
52-Week Low | $83.89 | $1.14 |
Enterprise Value | $6.53B | $284.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
PLBY trades at $1.17, up 0.86% today, but remains in a bearish technical trend. The company reported Q1 2026 revenue of $30.2 million with a narrowed net loss of $4.0 million, showing operational improvement. Recent news includes inclusion in Russell indexes and a major share repurchase. Despite negative ROE and high debt, analyst sentiment is positive with 75% buy ratings.
The outlook hinges on continued EBITDA growth and debt management. Opportunities include brand licensing momentum and cost controls. Key risks are persistent net losses, high leverage, and competitive pressures. Investors should weigh analyst optimism against fundamental challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
